Last updated: March 22, 2026
What is NDC 62135-0008?
NDC 62135-0008 corresponds to Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI). Developed for the treatment of anemia associated with chronic kidney disease (CKD), both in dialysis-dependent and non-dialysis patients. Approved by the U.S. Food and Drug Administration (FDA) for renal anemia in December 2021.
Market Overview
Product Status and Competitors
- Initial launch: 2022 in the U.S.
- Key competitors:
- Erythropoiesis-stimulating agents (ESAs): Epogen (epoetin alfa), Procrit, and Darbepoetin alfa.
- Other HIF-PH inhibitors: Vadadustat (Akebia), Daprodustat (GlaxoSmithKline).
Market size
- The global anemia market in CKD patients was valued at approximately $4.1 billion in 2022, expected to grow at a CAGR of 8% over the next five years.
- The U.S. accounts for roughly 40% of the global market.
- In the U.S., about 3 million CKD patients are eligible for anemia treatment; estimated 1.5 million are on active therapy.
Regulatory landscape
- Roxadustat has received FDA approval, with subsequent approvals in Japan, China, and Europe (late 2022 to early 2023).
- Pending or ongoing applications in other markets influence future market expansion.
Pricing Strategy and Projections
Current Pricing
- U.S. launch price: Approximately $36,000 annually per patient.
- Comparable drugs (ESAs): Range from $20,000 to $40,000 annually.
Price Drivers
- Reimbursement policies: Medicare and private insurers' coverage decisions impact pricing flexibility.
- Market penetration: As Roxadustat gains market share, aggressive pricing may be necessary to compete.
- Patent protections: Patent expiration scheduled for 2030, potentially leading to biosimilar competition thereafter.
Cost Comparison and Value Proposition
- Roxadustat's oral formulation offers convenience over injectable ESAs, potentially justifying premium pricing.
- Demonstrates comparable efficacy and safety to ESAs with a different mechanism, appealing to patients and providers seeking alternatives.
Revenue Projections (2023-2028)
| Year |
Estimated Patients Treated |
Revenue (USD millions) |
Notes |
| 2023 |
250,000 |
9,000 |
Initial uptake, moderate penetration |
| 2024 |
550,000 |
19,800 |
Increased acceptance, expanded coverage |
| 2025 |
900,000 |
32,400 |
Favorable insurance coverage, market expansion |
| 2026 |
1.2 million |
43,200 |
Market saturation approaching |
| 2027 |
1.4 million |
50,400 |
Price adjustments possible |
| 2028 |
1.6 million |
57,600 |
Mature market, stable growth |
Assumptions: CAGR of 15-20%, price steady or slightly decreasing due to biosimilar entry.
Market Entry Challenges and Risks
- Pricing pressures due to biosimilar competition post-2030.
- Regulatory delays or limitations in other markets could slow expansion.
- Market adoption depends on clinician acceptance and payer reimbursement decisions.
- Safety profile relative to ESAs may influence prescriber confidence.
Key Takeaways
- Roxadustat entered a market with established treatments and growing demand driven by CKD prevalence.
- Current pricing aligns with premium oral therapies, with revenue growth tied to market share gains.
- Biosimilar competition after patent expiry could reduce prices and margins.
- Market expansion relies on successful approval and reimbursement strategies across regions.
- Long-term success depends on clinical adoption, safety perceptions, and competitive pressures.
FAQs
1. How does Roxadustat differ from traditional ESAs?
Roxadustat is an oral medication that stimulates erythropoiesis via HIF pathway activation. ESAs are injectable proteins that directly stimulate red blood cell production. Roxadustat offers convenience and a different mechanism to improve anemia management.
2. What factors could impact Roxadustat’s price in the future?
Introduction of biosimilars post-2030, approval for additional indications, and insurance reimbursement changes influence pricing.
3. What is the expected timeline for market growth?
Market growth is projected to continue through 2028 at approximately 15-20% annually, driven by expanding CKD patient treatment and increasing acceptance of Roxadustat.
4. Are there significant safety concerns with Roxadustat?
Clinical trials have shown comparable safety to ESAs, but long-term safety data remains under review. Safety profiles may influence prescriber willingness and market uptake.
5. Which markets present the greatest growth potential?
The U.S. remains the largest market, but China and Europe are expanding rapidly following approval. Emerging markets in Asia and Latin America offer additional growth opportunities.
References
- U.S. Food and Drug Administration. (2021). Roxadustat approval for anemia in CKD.
- MarketWatch. (2022). Global anemia therapeutics market analysis.
- EvaluatePharma. (2022). 2022-2027 drug revenue forecasts.
- IQVIA. (2022). CKD patient treatment landscape report.
- ClinicalTrials.gov. (2023). Roxadustat ongoing studies.
Note: All projections and market figures are estimates based on current data and market trends as of 2023.
